Trial · NCT00352664
The Effect of Donepezil on Sedation and Other Symptoms
NCT00352664, Phase 3, Terminated, M.D. Anderson Cancer Center; results first posted 2009-12-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Donepezil on Sedation and Other Symptoms. Trials, record NCT00352664. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00352664
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Donepezil on Sedation and Other Symptoms
- NCT number
- NCT00352664
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 27 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Advanced Cancer
- Interventions
- Donepezil, Placebo
- First posted
- 2006-07-14
- Last updated
- 2016-05-09
- Results first posted
- 2009-12-29
- Limitations and caveats
- Insufficient drug supply and low patient accrual closed study early.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sedation Mean Scores at 1-Week | Baseline and Day 7 | Anderson Symptom Assessment Scale (ASAS) was used to measure sedation mean scores (SD) on a 0-10 scale with 0 representing "not drowsy" and 10 representing "worst possible drowsiness." |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Sedation Mean Scores at 1-Week | Baseline and Day 7 | Analysis was intention to treat (ITT), and population analyzed was that treated. Study closed early due to low patient accrual and insufficient supply of drug. No patients were randomized to Placebo Arm. | Scores on a Scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Sedation Mean Scores at 1-Week | Donepezil | Baseline | 6.44 | Standard Deviation 1.2 | Scores on a Scale |
| Sedation Mean Scores at 1-Week | Donepezil | Day 7 | 4.81 | Standard Deviation 2.6 | Scores on a Scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Donepezil | 27 | |
| Overall Study | STARTED | Placebo | 0 | |
| Overall Study | COMPLETED | Donepezil | 20 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Donepezil | 7 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea/vomiting | Gastrointestinal disorders | Donepezil | 6 | 20 | 6 |
| other | Nausea/vomiting | Gastrointestinal disorders | Placebo | 0 | 0 | 0 |
| other | Diarrhea | Gastrointestinal disorders | Donepezil | 5 | 20 | 5 |
| other | Diarrhea | Gastrointestinal disorders | Placebo | 0 | 0 | 0 |
| other | Anorexia | General disorders | Donepezil | 4 | 20 | 4 |
| other | Anorexia | General disorders | Placebo | 0 | 0 | 0 |
| other | Muscle Cramps | General disorders | Donepezil | 2 | 20 | 2 |
| other | Muscle Cramps | General disorders | Placebo | 0 | 0 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Donepezil | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Donepezil | 17 | 20 |
| Total, other adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Donepezil | 0 | 20 |
| Total, serious adverse events | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00352664
GET https://conductscience.org/api/trials/v1/NCT00352664/registered